The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable

American Journal of Epidemiology

Volumn 174, Issue 12, 2011, Pages 1382-1390

  Ahern, Thomas P ^a   Pedersen, Lars ^a   Sværke, Claus ^a   Rothman, Kenneth J ^a   Sørensen, Henrik Toft ^a   Lash, Timothy L ^a  

^a NONE

Author keywords

Anticoagulants; Bias (epidemiology); Heart valves; Instrumental variable; Neoplasms; Vitamin K

Indexed keywords

ANTIVITAMIN K;

ANTAGONISM; CANCER; CARDIOVASCULAR DISEASE; COAGULATION; COHORT ANALYSIS; DISEASE INCIDENCE; EPIDEMIOLOGY; GAUSSIAN METHOD; POISSON RATIO; REGRESSION ANALYSIS; VITAMIN;

ADULT; AGED; ARTICLE; BAYES THEOREM; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; FEMALE; HEART VALVE REPLACEMENT; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NORMAL DISTRIBUTION; POISSON DISTRIBUTION; POPULATION RESEARCH; PRESCRIPTION; RECIPIENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DENMARK; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; VITAMIN K; YOUNG ADULT;

DENMARK;

EID: 83755225711     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr268     Document Type: Article

References (39)

1. Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol. 2001;106(1-2):18-24. (Pubitemid 32830512)
2. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood. 1983;62(1): 14-31. (Pubitemid 13070586)
3. Agnelli G, Taliani MR, Prandoni P. More on: vitamin K antagonists and cancer. WODIT Investigators. J Thromb Haemost. 2008;6(8):1441-1442; author reply 1442-1443. (Pubitemid 352016332)
4. Di Nisio M, Buller HR, Porreca E. Do low-molecular-weight heparins improve the survival of cancer patients? Nat Clin Pract Oncol. 2005;2(12):612-613. (Pubitemid 43179720)
5. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130-2135. (Pubitemid 46218704)
6. Piccioli A, Falanga A, Prandoni P. Anticoagulants and cancer survival. Semin Thromb Hemost. 2006;32(8):810-813. (Pubitemid 44956976)
7. Goodman LS, Gilman A, Brunton LL, et al. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006.
8. Katzung BG. Basic and Clinical Pharmacology. 9th ed. New York, NY: Lange Medical Books/McGraw Hill; 2004.
9. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA. 1981;245(8): 831-835. (Pubitemid 11135890)
10. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984;53(10):2046- 2052. (Pubitemid 14101772)
11. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med. 2000;342(26):1953-1958. (Pubitemid 30419090)
12. Eikelboom JW, Mehta SR. Venous thromboembolism and cancer [letter]. N Engl J Med. 2000;343(18):1337. author reply 1338.
13. Hughes-Davies TH. Venous thromboembolism and cancer [letter]. N Engl J Med. 2000;343(18):1337. author reply 1338.
14. Roychowdhury D. Venous thromboembolism and cancer [letter]. N Engl J Med. 2000;343(18):1337-1338.
15. Zacharski LR, Ornstein DL. Venous thromboembolism and cancer [letter]. N Engl J Med. 2000;343(18):1338.
16. Zielinski CC, Hejna M. Warfarin for cancer prevention. N Engl J Med. 2000;342(26):1991-1993. (Pubitemid 30419098)
17. Taliani MR, Agnelli G, Prandoni P, et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. Warfarin Optimal Duration Italian Trial (WODIT) Investigators. J Thromb Haemost. 2003;1(8):1730-1733.
18. BlumentalsWA, Foulis PR, Schwartz SW, et al. Does warfarin therapy influence the risk of bladder cancer? Thromb Haemost. 2004;91(4):801-805. (Pubitemid 38477462)
19. Tagalakis V, Tamim H, Blostein M, et al. Use of warfarin and risk of urogenital cancer: A population-based, nested casecontrol study. Lancet Oncol. 2007;8(5):395-402. (Pubitemid 46621759)
20. Pengo V, Noventa F, Denas G, et al. Long-term use of vitamin K antagonists and incidence of cancer: A population-based study. Blood. 2011;117(5):1707-1709.
21. Pengo V, Denas G, Jose SP, et al. Cancer prevention and vitamin K antagonists: an overview. Thromb Res. 2010; 125(suppl 2):S103-S105.
22. Hernán MA, Robins JM. Instruments for causal inference: an epidemiologist's dream? Epidemiology. 2006;17(4): 360-372. (Pubitemid 44305508)
23. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006;114(5): e84-e231. (Pubitemid 44268973)
24. Lash TL, Cole SR. Immortal person-time in studies of cancer outcomes. J Clin Oncol. 2009;27(23):e55-e56.
25. Storm HH, Michelsen EV, Clemmensen IH, et al. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull. 1997;44(5):535-539.
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5): 373-383. (Pubitemid 17055592)
27. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. Oslo, Norway: Norwegian Institute of Public Health; 2008. (http://www.whocc.no/atcddd/). (Accessed 2008).
28. Aurigemma GP, Gaasch WH. Antithrombotic therapy in patients with prosthetic heart valves. In: Otto CM, ed. UpToDate. Waltham, MA: UpToDate; 2010.
29. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(4):722-729. (Pubitemid 30612241)
30. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37-48. (Pubitemid 29014427)
31. Brookhart MA, Wang PS, Solomon DH, et al. Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology. 2006;17(4):373-374. (Pubitemid 44305509)
32. Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006; 17(3):268-275.
33. Cunnane C. Unbiased plotting positions-a review. J Hydrol. 1978;37:205-222.
34. Steenland K, Bray I, Greenland S, et al. Empirical Bayes adjustments for multiple results in hypothesis-generating or surveillance studies. Cancer Epidemiol Biomarkers Prev. 2000;9(9):895-903.
35. Sørensen HT, Johnsen SP, Nørgård B, et al. Cancer and venous thromboembolism: A multidisciplinary approach. Clin Lab. 2003;49(11-12):615-623. (Pubitemid 37493459)
36. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet. 1998;351(9109):1077-1080. (Pubitemid 28163410)
37. Sørensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338(17): 1169-1173. (Pubitemid 28180744)
38. Rothman KJ, Greenland S, Lash TL. Validity in epidemiologic studies. In: Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:128-147.
39. Storm HH, Pihl J, Michelsen E, et al, eds. Cancer Incidence in Denmark, 1993. Copenhagen, Denmark: Danish Cancer Society; 1996.